1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase Ib/II open-label study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+) and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 Part 4
    Meeting Abstract

    Janjigian, Y. Y.; Lloyd, C.; de Giorgio-Miller, V. G.; Chang, Y. T.; Lee, J.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Kudo, M.; Rimassa, L.; Chan, S. L.; Sangro, B.; Lau, G.; Breder, V. V.; Varela, M.; Crysler, O. V.; Bouattour, M.; Dao, V. T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • EDGE-Gastric Arm A1: Phase II study of domvanalimab (D), zimberelimab (Z), and FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer
    Meeting Abstract

    Rha, S. Y.; Oh, D. Y.; Pelster, M.; Wainberg, Z. A.; Sison, A.; Scott, J.; Nelson, S.; Wishengrad, D.; Rhee, J.; Nuyten, D. S. A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
    Meeting Abstract

    Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Weber, P. E. Y.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes by comorbidities with tremelimumab and durvalumab in the phase 3 Himalaya study in unresectable hepatocellular carcinoma
    Meeting Abstract

    Rimassa, L.; Dayyani, F.; Kelley, R. K.; Sangro, B.; Chan, S. L.; McCoy, C. L.; Paskow, M. J.; Makowsky, M.; Gupta, C.; Ran, D.; more...
    Hepatology (2024)

    Fulltext@MSK | Save
  • Five-year overall survival and overall survival by tumor response measures from the phase 3 Himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Meeting Abstract

    Rimassa, L.; Chan, S.; Sangro, B.; Lau, G.; Kudo, M.; Breder, V.; Varela, M.; Crysler, O.; Bouattour, M.; Dao, T. V.; more...
    Hepatology (2024)

    Fulltext@MSK | Save
  • Non-viral etiology subgroup of the phase 3 Himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Meeting Abstract

    Reig, M.; Tam, V.; Sangro, B.; Archambeaud, I.; Kelley, R. K.; Chan, S.; Kudo, M.; Masi, G.; Paskow, M.; Makowsky, M.; more...
    Hepatology (2024)

    Fulltext@MSK | Save
  • Bayesian hierarchical model for heterogeneity in the diagnosis and treatment of hepatocellular carcinoma (HCC) in the African continent
    Journal Article

    Capanu, M.; Li, Y.; Chou, J.; Gönen, M.; Abou-Alfa, G. K.
    Communications in Statistics Case Studies Data Analysis and Applications (2024)

    Fulltext@MSK | Save
  • Balancing anticancer therapy efficacy and safety in advanced hepatocellular carcinoma: A case report
    Journal Article

    Mourad, M.; Al Mahmasani, L.; Abbas, N.; Sainamthip, P.; Freile, B.; Zayed, A.; Alsuwailem, R.; Khatib, O.; Sinno, S.; Sabatin, F.; more...
    Journal of Gastrointestinal Oncology (2024)

    Fulltext@MSK | Save
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Möhler, M.; Janjigian, Y.; Al-Batran, S. E.; Wainberg, Z.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L.; Oh, D. Y.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save